Evidence map›Paper›PMID 23829765›Full record

ArticleMolecular pharmaceutics2013

Targeted delivery of antisense oligonucleotides by chemically self-assembled nanostructures.

Amit Gangar, Adrian Fegan, Sidath C Kumarapperuma, Peter Huynh, Alexey Benyumov, Carston R Wagner

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Amit GangarDepartment of Medicinal Chemistry and §Department of Chemistry, University of Minnesota , Minneapolis, Minnesota 55414, United States.
Adrian Fegan
Sidath C Kumarapperuma
Peter Huynh
Alexey Benyumov
Carston R Wagner
Institute of Medicinal Plant Development · CNTwin Cities Orthopedics · USUniversity of Minnesota · US

Funding

Chemically Controlled Assembly of Therapuetic Protein NanostrcturesR01CA120116 · NCI · UNIVERSITY OF MINNESOTA · PI WAGNER, CARSTON R. · 2007 to 2010
$1.2M
Self-Assemblying Immunotherapeutic NanoringsR01CA125360 · NCI · UNIVERSITY OF MINNESOTA · PI WAGNER, CARSTON R. · 2008 to 2011
$1.2M
NCI NIH HHS CA120116NCI NIH HHS CA125360NCI NIH HHS R01 CA120116NCI NIH HHS R01 CA125360
6 · The paper itself

Abstract

Synthetic nucleic acids have shown great potential in the treatment of various diseases. Nevertheless, the selective delivery to a target tissue has proved challenging. The coupling of nucleic acids to targeting peptides, proteins, and antibodies has been explored as an approach for their selective tissue delivery. Nevertheless, the preparation of covalently coupled peptides and proteins that can also undergo intracellular release as well as deliver more than one copy of the nucleic acid has proved challenging. Recently, we have developed a novel method for the rapid noncovalent conjugation of nucleic acids to targeting single chain antibodies (scFv) using chemically self-assembled nanostructures (CSANs). CSANs have been prepared by the self-assembly of two dihydrofolate reductase molecules (DHFR(2)) and a targeting scFv in the presence of bis-methotrexate (bis-MTX). The valency of the nanorings can be tuned from one to eight subunits, depending on the length and composition of the linker between the dihydrofolate reductase molecules. To explore their potential for the therapeutic delivery of nucleic acids as well as the ability to expand the capabilities of CSANs by incorporating smaller cyclic targeting peptides, we prepared DHFR(2) proteins fused through a flexible peptide linker to cyclic-RGD, which targets αvβ3 integrins, and a bis-MTX chemical dimerizer linked to an antisense oligonucleotide (bis-MTX-ASO) that has been shown to silence expression of eukaryotic translation initiation factor 4E (eIF4E). Monomeric and multimeric cRGD-CSANs were then prepared with bis-MTX-ASO and shown to undergo endocytosis in the breast cancer cell line, MDA-MB-231, which overexpresses αvβ3. The bis-MTX-ASO was shown to undergo endosomal escape resulting in the knock down of eIF4E with at least the same efficiency as ASO delivered by oligofectamine. The modularity, flexibility, and common method of conjugation may prove to be a useful general approach for the targeted delivery of ASOs, as well as other nucleic acids to cells.

Indexed as

Cell Line, TumorHumansModels, BiologicalNanostructuresNanotechnologyNucleic AcidsOligonucleotides, AntisenseNucleic AcidsOligonucleotides, Antisense

Identifiers

PMID23829765
PMCPMC5568898
OpenAlexW1982380030

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.